2026-10-11T18:37:49Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34040696 2026-10-01T07:20:11Z category_37339 category_37357 category_37363 portal_1012 item_type_6 month_year_10_2026

Supplementary Figure S3 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT) Ferdinandos Skoulidis (16041866) Salma K. Jabbour (25153919) Edward B. Garon (15033509) Puneeth Iyengar (25153922) Giorgio Scagliotti (25153925) Loïc Ferrer (25153928) Guillaume Etchepare (25153931) Olivier Gallinato (25153934) Jérôme Faure (25153937) Paul Bernard (25153940) Thierry Colin (25153943) Philippe Menu (25153946) Yian Lin (25153949) Ling Cai (25153952) Ammar Ahmed Chaudhry (25153955) Amanda Remorino (25153958) Ross Stewart (14851015) Luisa Luciani-Silverman (25153961) Katy Miller (25153964) David Dellamonica (25153967) Jolyon Faria (25153970) Yiduo Zhang (25153973) Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Imaging biomarkers Clinical Imaging Immunology Antibodies/immunoconjugates Immunotherapy Checkpoint blockade Lung Cancer <p>Supplementary Figure 3. Partial dependence plots (PDPs) for (A) Model 4, analysis set 2 (clinical and radiomics); (B) Model 7, analysis set 3 (clinical and genomics); (C) Model 19, analysis set 6 (clinical and genomics, non-squamous patients only). The PDPs show the predicted CATE against the selected feature, by averaging the model's predictions over all patients with that feature set to a specific value and all other features held constant. Panel A shows PDPs for the top 5 features in Figure 3A, panel 3. Panel B shows PDPs for the top 5 features in Figure 3B, panel 3. Panel C shows PDPs for the top 5 features in Figure 3C, panel 3.</p> 2026-10-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34040696 https://figshare.com/articles/journal_contribution/Supplementary_Figure_S3_from_Utilizing_Machine_Learning_to_Identify_Multimodal_Signatures_for_Patients_Who_Would_Benefit_from_the_Addition_of_Tremelimumab_to_Durvalumab_and_Chemotherapy_TRIDENT_/34040696 CC BY